Apos therapy evidence for UK patients: 2 year gains and clinic pathway
Randomised trial data and a two-year follow-up study show statistically significant improvements in pain and function for knee osteoarthritis patients using Apos therapy compared with sham devices. NICE has reviewed this evidence and issued a conditional recommendation, noting that while the results are real, it remains unclear whether every patient will experience a change large enough to notice day to day. Treatment also depends heavily on clinician calibration and consistent daily wear.
TL;DR:
Apos therapy shows statistically significant pain and function improvements within the first eight weeks, with benefits generally maintained at two years.
The strongest evidence comes from a two-year prospective follow-up study and a high-quality randomized controlled trial against sham devices.
NICE recommends Apos only for patients who wish to delay or avoid knee surgery after failing standard non-surgical care, not as a first-line treatment.
Effectiveness depends heavily on consistent daily wear, proper calibration, and follow-up by a trained clinician, highlighting the importance of adherence.
Long-term cost savings are uncertain, as benefits’ duration and impact on delaying surgery are still under evaluation, with more real-world data needed.
Table of Contents
What the peer-reviewed clinical studies show
The strongest piece of Apos therapy evidence comes from a two-year prospective follow-up published in the Journal of Orthopaedic Surgery and Research, which tracked patients using validated outcome measures rather than relying on self-reported satisfaction alone. The study found statistically significant improvements in WOMAC pain, stiffness, and function scores in the treated group compared with controls, and crucially, those gains held at the two-year mark rather than fading after the initial novelty of a new device wore off. That durability is what separates a therapy worth discussing from one that produces a short-lived placebo bump.
The two-year followup study also reported changes across the SF-36 quality of life measure and the Knee Society Score (KSS), giving a broader picture than pain scores alone. Most of the improvement appeared within the first eight weeks of treatment, which matters for anyone wondering whether Apos therapy for knee osteoarthritis is a slow-burn intervention or something with a faster feedback loop. It leans towards the latter, though the trajectory then flattens into a maintenance phase rather than continued dramatic gains.
Pro Tip: If you’re comparing Apos therapy reviews online, look for ones that mention specific WOMAC or KSS score changes rather than general statements like “felt much better.” Vague testimonials tell you little about whether the effect would hold up in a controlled setting.
A registered randomised controlled trial, Clinicaltrials, was designed to strengthen this evidence base further. The trial planned to randomise 220 patients 1:1 against a matched sham device, with pain at 24 weeks as the primary outcome and gait analysis included as a secondary measure. Patient-blind design of this kind matters because it controls for the expectation effect that inflates results in open-label device studies. Even a well-designed exercise programme can show inflated benefit when patients know exactly what they’re using and expect it to help.
Where the picture gets murkier is in comparing across the wider evidence base. NICE’s external assessment group (EAG) identified one high-quality RCT, the prospective 2-year comparative study, and a scattering of additional observational studies feeding into the overall picture of apos therapy research.
One high-quality RCT versus sham device, providing the cleanest causal evidence available
A prospective comparative study following patients for two years, showing durability of effect
Multiple observational and non-comparative studies, consistent in direction but carrying higher risk of bias
No direct head-to-head trials against defined non-surgical standard care, which remains a real gap
Different studies also used slightly different WOMAC scales and scoring conventions, which complicates pooling results into a single number. Sample sizes across the observational studies tend to be modest, and few control for the full range of confounders a sceptical reader would want ruled out. Whether a measurable reduction in joint loading during gait translates into a difference a patient actually notices in daily life is the debate that NICE’s own assessment leaves unresolved, and it’s the same distinction between statistical significance and clinical meaningfulness that runs through the rest of this evidence base.
How NICE assessed Apos therapy and what it actually recommends
NICE’s evaluation of AposHealth, published under project HTG671, gives the clearest independent verdict available on whether Apos therapy for knee osteoarthritis holds up under scrutiny. The guidance is conditional, not a blanket endorsement, and the wording matters.
Apos may improve pain and function compared with sham devices, but the clinical meaningfulness of that improvement for all patients remains uncertain, and further real-world data collection is recommended before use expands more broadly.
That single sentence captures the tension running through the entire evidence base. The NICE HTG671 evidence review recommends Apos specifically for patients who meet referral criteria for knee replacement, want to avoid surgery, and have not found sufficient relief through standard non-surgical care such as physiotherapy or weight management. It is not positioned as a first-line treatment for mild osteoarthritis, and NICE was explicit that the recommendation applies to a defined cohort rather than every person with a sore knee.
The EAG’s evidence synthesis fed directly into that conditional stance. Reviewing one high-quality RCT, one prospective 2-year comparative follow-up, and a wider set of observational studies, the assessment group found consistent direction of benefit but flagged specific limitations:
No trials directly compared Apos against a clearly defined non-surgical standard-care programme, leaving a genuine evidence gap
The economic modelling used to project cost savings relies on assumptions that are sensitive to how long benefits are assumed to last
Observational data, while broadly supportive, carries a higher risk of bias than the randomised evidence
Long-term outcomes beyond two years remain thinly studied compared with the eight-week and two-year data points
NICE’s own insight on the assessment is that the statistical case is solid but the practical case for universal use is not yet proven, which is why the guidance leans towards selective use with local outcome tracking rather than blanket rollout. That’s a meaningfully different message from either “NICE approved it” or “NICE rejected it,” and it’s worth understanding precisely because so much marketing copy flattens the nuance in one direction or the other.
How Apos therapy works: device, calibration and treatment pathway
Apos therapy is built around a biomechanical device fitted with adjustable elements known as pertupods, mounted under a shoe-like platform the patient wears during daily activity. The pertupods can be repositioned to shift how weight travels through the leg during walking and standing, which is the mechanism behind the reduction in knee varus moment observed in gait studies. The theory, and the evidence supports this to a reasonable degree, is twofold: unloading the parts of the joint bearing excess stress, and retraining the neuromuscular patterns that control how someone walks.
This is not an off-the-shelf orthotic you buy and forget about. Calibration requires a clinician to assess gait, adjust pertupod position, and refine the setup over multiple sessions, because the correct configuration for one patient’s knee osteoarthritis will differ from another’s hip presentation.
A typical programme runs roughly as follows:
Initial gait assessment. A clinician analyses walking pattern, pain points, and joint loading before any device is fitted.
Device calibration. Pertupods are set and adjusted in clinic, with the patient walking under supervision to check the response.
Home wear period. Patients wear the device for a set number of hours daily, building up gradually as tolerated.
Follow-up recalibration. Return visits over roughly a year allow the clinician to fine-tune settings as gait and symptoms change.
Pro Tip: Treat the daily wear target as a non-negotiable part of the programme, not a suggestion. The two-year follow-up data reflects patients who actually wore the device consistently. Skipping days is one of the most common reasons results fall short of what the trials reported.
Who is likely to benefit and who should look elsewhere
The trial and NICE-eligible population is more specific than general marketing around Apos therapy benefits sometimes suggests. NICE’s guidance targets people who meet referral criteria for knee replacement, would prefer to avoid or delay surgery, and have already tried standard non-surgical care such as physiotherapy, weight management, or pain medication without adequate relief. If you’re earlier in the osteoarthritis journey and haven’t exhausted conservative options, a structured physiotherapy programme for knee osteoarthritis is usually the sensible starting point rather than jumping straight to a device-based approach.
Certain factors point away from Apos therapy or towards a orthopaedic referral instead:
Severe structural joint damage where surgery is already clearly indicated and delay carries risk
Balance or neurological conditions that make wearing an unstable platform device unsafe
Active joint infection, recent fracture, or other acute conditions requiring medical management first
An inability or unwillingness to commit to daily wear and multiple follow-up appointments
That last point deserves more weight than it usually gets. Care Opinion feedback on APOS-style services shows a real split between patients reporting strong benefit and those reporting disappointment or early discontinuation, and the difference often traces back to how consistently the device was actually worn and how closely follow-up was maintained. Apos therapy versus orthotics is sometimes framed as a straight comparison of devices, but the more accurate framing is that Apos is an active, supervised programme, while a standard orthotic is typically a passive support. That distinction affects who’s a realistic candidate as much as any clinical criterion does.
What to expect and when
Most people using Apos therapy for knee osteoarthritis notice the bulk of their improvement within the first eight weeks, according to the two-year followup data. Gains in WOMAC pain and function scores tend to stabilise from around three to six months, provided the wear schedule is maintained, and the same study found those improvements were still measurable at the two-year mark rather than tailing off.
The outcome measures used across the research map to different aspects of daily life, and it helps to know which ones show the clearest evidence:
WOMAC pain, stiffness and function carries the strongest and most consistent supporting data across studies
SF-36 quality of life shows meaningful movement but with more variability between individuals
KSS (Knee Society Score) improved in the two-year data, reflecting both pain and functional capacity
Gait metrics, particularly knee varus moment, show the clearest biomechanical explanation for why the clinical scores move
Not everyone responds equally. Some patients report only modest change, and a smaller group discontinues altogether, often linked to inconsistent wear rather than the device failing to work as designed. Setting expectations around an eight-week early signal, followed by a longer plateau, is more realistic than expecting linear or dramatic week-on-week improvement.
Costs, NHS pilot results and what the numbers mean for you
Programme cost figures cited in NICE consultation documents put the typical AposHealth programme cost in a range excluding VAT, covering the device components, clinician training, and access to clinical tracking software. That figure sits in a broadly similar range to the hidden costs some patients encounter with orthotic pricing in the UK, where an initial quote often understates the full course of fittings and adjustments needed.
An NHS Supply Chain pilot embedding APOS into a knee osteoarthritis pathway reported early measurable improvements in mobility and pain across a small patient group, alongside a substantial reported cost saving and a strong return on investment in that pilot setting.
The pilot demonstrated that clinically led, cost-neutral innovation is achievable when APOS is embedded within a structured referral pathway rather than offered as a standalone add-on.
That framing from the NHS Supply Chain pilot report matters because it ties the savings to how the therapy was integrated into referral criteria and follow-up, not simply to the device itself.
NICE’s own economic modelling adds an important caveat to that optimism. The EAG’s base case found AposHealth could be cost saving at five years, driven mainly by reduced rates of total knee replacement, but sensitivity analysis showed the model can shift towards cost incurring over ten to twenty years depending on the assumptions used.
For an individual patient, cost is a fairly fixed, upfront figure tied to the programme itself. For a healthcare provider weighing wider adoption, the calculation is longer-term and depends on how many knee replacements the therapy genuinely defers, which is precisely the uncertainty NICE flagged.
What an Apos assessment looks like at Parkstherapycentre
Assessing suitability for Apos-style biomechanical therapy starts the same way the clinical evidence suggests it should: with a proper gait and functional assessment before any device decisions are made. At Parkstherapycentre, that begins with a physiotherapy assessment to establish the baseline picture of pain, range of movement, and walking pattern, followed by outcome measure tracking so that progress can be judged against something more concrete than how a patient feels on a given day.
A typical first-appointment sequence looks like this:
Initial physiotherapy assessment covering pain history, joint range, and gait observation
Discussion of whether device calibration is appropriate against the criteria NICE outlines for eligible patients
Baseline recording of relevant outcome measures to compare against later follow-up
Agreement of a realistic wear schedule and a follow-up calendar for recalibration
Patients preparing for a first appointment benefit from wearing their usual footwear and bringing a note of when pain flares tend to occur during the day, since that detail feeds directly into gait assessment. Our guide to the APOS therapy assessment process walks through what clinicians look for during calibration in more detail.
Pro Tip: Bring a short diary of your pain pattern over the previous week, noting whether it’s worse in the morning, after walking, or at the end of the day. That single piece of information often shapes calibration decisions more than a single in-clinic assessment can.
Progress is monitored through repeat measures at agreed intervals rather than left to subjective impression, which matches the approach the underlying research itself relies on to judge whether a treatment is genuinely working.
Clinical perspective: evidence, preference and shared decisions
The honest reading of this evidence base is that Apos therapy earns a place in the conservative care pathway for a defined group of patients, not a blanket recommendation for anyone with a sore knee. NICE’s own hesitation about clinical meaningfulness is a strength of the guidance, not a weakness. It forces clinicians to keep measuring rather than assuming a statistically significant trial result automatically means a good outcome for the person in front of them.
Where this matters practically is in shared decision making. A patient weighing Apos against continued physiotherapy, or against eventual surgery, deserves to know that the eight-week signal is real, that two-year durability data exists, and that the model for long-term cost savings still carries genuine uncertainty. Objective outcome tracking, ideally contributing to wider registry or audit data, is what will eventually close the evidence gap NICE identified around head-to-head comparisons with standard non-surgical care. Until then, the responsible position is neither dismissal nor overpromise.
— Ivan
Book an Apos therapy assessment at Parkstherapycentre
A local therapy centre offers a route into structured biomechanical assessment rather than leaving you to interpret trial data alone and guess whether Apos therapy fits your situation. The multidisciplinary team combines physiotherapy assessment with device-based therapies, so calibration decisions are grounded in gait analysis and outcome tracking similar to that used in the research.
A Physiotherapy Assessment costs £76 as a one-off session and establishes the baseline needed before any device calibration begins, with a standard Physiotherapy Treatment session priced at £67. Most major health insurance plans are accepted alongside private payment, and appointments can be booked directly online across the clinic’s Bedfordshire and Buckinghamshire locations. If ongoing conservative management alongside device therapy makes sense for your presentation, acupuncture for knee pain is also available as a complementary option. Clinics considering how to communicate this kind of evidence-based service more widely may also find value in specialist marketing support for therapists.
To take the next step, visit the full price list and booking page to check current appointment availability and book a physiotherapy assessment as your starting point.
Sources
The claims made throughout this article draw on a small set of primary documents worth reading directly if you want to verify the evidence yourself.
Long‑Term Effects of AposTherapy in Patients with Osteoarthritis of the Knee: A Two‑Year Followup
AposHealth for knee osteoarthritis: evidence review (NICE HTG671 project documents)
Clinically led, cost‑neutral innovation with APOS (NHS Supply Chain)
Clinical trial record: APOS therapy randomized trial (NCT02363712)
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
FAQ
Does Apos therapy actually work?
Trial evidence shows statistically significant improvements in pain and function scores compared with sham devices, with gains often appearing within eight weeks and holding at two years in follow-up data. NICE has issued a conditional recommendation for a specific patient group, rather than declaring it effective for everyone with osteoarthritis.
What is the newest development in treating knee osteoarthritis?
Biomechanical devices like Apos, alongside NICE-reviewed technologies, represent one of the more actively researched non-surgical approaches, particularly for patients trying to delay or avoid knee replacement. Ongoing randomised trials such as NCT02363712 continue testing device-based approaches against sham controls to strengthen the evidence base further.
What is the biggest mistake that makes knee pain worse?
Inconsistent adherence, whether to a wear schedule for a device or to a prescribed exercise programme, is one of the most common reasons results fall short of what trials report. A structured physiotherapy programme for knee osteoarthritis with regular follow-up tends to outperform sporadic self-managed efforts.
How much does Apos therapy cost?
Programme cost figures cited in NICE consultation documents put a typical course at around £816 to £875 excluding VAT, covering device components, clinician training, and tracking software access. At Parkstherapycentre, the starting point is a Physiotherapy Assessment priced at £76, which establishes whether device calibration is an appropriate next step for your presentation.
Recommended